| 제목 | Impact of fear of cancer recurrence on survival among lymphoma patients. | ||
|---|---|---|---|
| 작성자 | 관리자 | 등록일 | 2019-12-13 |
내용
Psychooncology. 2019 Oct 26. doi: 10.1002/pon.5265. [Epub ahead of print]
Impact of fear of cancer recurrence on survival among lymphoma patients.
Kim SJ1,2, Kang D3,4,5, Kim I5, Yoon SE2, Kim WS1,2, Butow PN6, Guallar E7, Cho J3,4,5,7.
Author information
- 1
- Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea.
- 2
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- 3
- Department of Clinical Research Design and Evaluation, Samsung Advanced Institute for Health Science and Technology, Sungkyunkwan University School of Medicine, Seoul, Korea.
- 4
- Center for Clinical Epidemiology, Samsung Medical Center, Sungkyunkwan University, Seoul, Korea.
- 5
- Cancer Education Center, Samsung Comprehensive Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- 6
- Centre for Medical Psychology and Evidence-based Decision-making, School of Psychology and Department of Medicine, University of Sydney, Sydney, NSW, Australia.
- 7
- Departments of Epidemiology and Medicine and Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Medical Institutions, Baltimore, Maryland.
Abstract
OBJECTIVE:
This study aimed to evaluate FCR among lymphoma patients who completed treatment and its impact on survival and quality of life (QOL).
METHODS:
In this prospective cohort study, 467 lymphoma patients were included who completed treatment with curative intent between Feb 2012 and March 2017. FCR was measured using a question from the Korean version of the QOL in Cancer Survivors Questionnaire. QOL and general health and functioning were measured using the EORTC QLQ-C30. Participants were actively followed up for all-cause and disease-specific mortality.
RESULTS:
In total, 16.3% of the patients had severe FCR. The adjusted Hazard Ratio (HR) for all-cause mortality comparing participants with and without severe FCR was 2.52 (95% CI = 1.15, 5.54), and the association was stronger in indolent non-Hodgkin's lymphoma (NHL) (HR = 6.77; 95% CI = 1.04, 43.92). Participants with severe FCR were also at higher risk of lymphoma-specific mortality (HR = 2.62; 95% CI = 1.13, 6.05) than patients without severe FCR. Patients with severe FCR had significantly worse general health status (64.3 vs. 71.0, p = 0.03) and physical (82.4 vs. 76.7, p <0.01), emotional (68.5 vs. 84.8, p <0.001), and social functioning (67.8 vs. 84.2, p <0.001) than patients without severe FCR.
CONCLUSIONS:
A substantial number of participants with lymphoma experience FCR after treatment completion, even in the case of indolent lymphomas. Given the negative impact of severe FCR on survival and general health and functional status, active monitoring and appropriate management of FCR should be considered in clinical settings.
